Cardiovascular Risk in Patients with Psoriatic Arthritis by Zhu, Tracy Y. et al.
Hindawi Publishing Corporation
International Journal of Rheumatology
Volume 2012, Article ID 714321, 11 pages
doi:10.1155/2012/714321
Review Article
Cardiovascular Risk in Patients with Psoriatic Arthritis
TracyY.Zhu, EdmundK.Li,andLai-ShanTam
Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong
Correspondence should be addressed to Lai-Shan Tam, lstam@cuhk.edu.hk
Received 10 January 2012; Revised 14 February 2012; Accepted 21 February 2012
Academic Editor: George D. Kitas
Copyright © 2012 Tracy Y. Zhu et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Psoriatic arthritis (PsA) is an inﬂammatory arthritis associated with psoriasis. In addition to skin and joint involvement, there is
increasingevidencesuggestingthatpatientswithPsAalsohaveanincreaseinriskofclinicalandsubclinicalcardiovasculardiseases,
mostly due to accelerating atherosclerosis. Both conventional and nonconventional cardiovascular risk factors contribute to the
increased cardiovascular riskin PsA.Chronicinﬂammation plays a pivotal role in the pathogenesis of atherosclerosis in PsA,acting
independently and/or synergistically with the conventional risk factors. In this paper, we discuss the current literature indicating
that patients with PsA are at risk of cardiovascular diseases.
1.Introduction
Psoriatic arthritis (PsA) is an immune-mediated inﬂamma-
tory arthritis associated with psoriasis. Annual incidence of
PsA ranges from 0.1 to 23.1 per 100,000, while prevalence
ranges from 1 to 420 per 100,000 [1]. Patients with PsA have
heterogeneous clinical presentations with diverse articular
and dermatological features as well as varied disease course
and outcomes. PsA can be a severe form of arthritis with
prognosis similar to that of rheumatoid arthritis (RA) [2–4].
In addition to skin and musculoskeletal involvement, there
is increasing evidence suggesting that patients with PsA also
have an increase in risk of cardiovascular disease (CVD) [5–
7]. The objective of this paper is to provide an overview
of the current literature indicating that patients with PsA
are at risk of CVD. A better knowledge of the association
between PsA and cardiovascular comorbidities can help in
earlymanagementandmodiﬁcationofriskfactors,minimize
the impact of the cardiovascular comorbidities, and improve
patients’ long-term outcome.
2.LiteratureSearch
Literature search was conducted using the PubMed database
up until January 2012. Key words for the search were “pso-
riatic arthritis” in combination with “mortality”, “cardio-
vascular disease”, “coronary heart disease”, “coronary artery
disease”, “cardiovascular risk”, “atherosclerosis”, “subclinical
atherosclerosis”, “endothelial function”, “lipids”, “hyperten-
sion”, “diabetes mellitus”, “homocysteine”, or “acute-phase
proteins” in the title, abstract, or key words with limits set to
include humans and studies written in English. Articles were
deemed eligible if they included (cardiovascular) mortality
and morbidity, and/or subclinical cardiovascular morbidity,
and/or data about cardiovascular risk factors, and/or the
eﬀects of treatment on cardiovascular risk in PsA. The initial
search yielded 528 abstracts, which were narrowed to 90
potentially relevant articles by preliminary review of the
titles and by excluding review articles and case report (n =
126). Twenty articles were deemed ineligible after examining
the abstracts. Full texts of the remaining 70 articles were
retrieved. The reference lists of retained papers were then
checked for any articles that the initial database search had
failed to identify, yielding 10 additional articles for full text
examination. The majority of articles excluded were due to
onlyprovidingdataonpatientswithpsoriasisorduetobeing
not relevant to the cardiovascular risk in PsA. In the end, 52
articles were deemed eligible for this paper.
The diagnostic criteria used in each included study
are not uniform. PsA was diagnosed as (seronegative)
inﬂammatoryarthritisassociatedwithpsoriasisin14studies.
Moll and Wright criteria for PsA and the ClASsiﬁcation for
Psoriatic ARthritis criteria were used in 9 and 10 studies,
respectively. Diagnosis of PsA was obtained from patient
charts or database in 6 studies. Thirteen studies did not
provide clear diagnostic criteria.2 International Journal of Rheumatology
Table 1: Mortality studies in psoriatic arthritis.
Study Year Country no. of
patients
Male, no.
[%]
Follow-up
period SMR (95% CI) Remarks Major causes
of death
Roberts et
al. [11] 1976 UK 168 — — — 18 deaths
occurred
9 deaths due
to CVD
Coulton et
al. [13] 1989 UK 40 16 (40) 8 years — No deaths
occurred —
Wong et
al. [8] 1997 Canada 428 234 (54.7) 1978 –1993
Overall: 1.62 (1.21–2.12)
Male: 1.65 (1.09, 2.04)
Female: 1.59 (1.04, 2.33)
—
CVD
(36.2%),
respiratory
disease
(21.3%)
Shbeeb et
al. [10] 2000 US 66 32 (48.5) 1982–1991 —
Similar
survival to
the general
population
—
McHugh
et al. [3] 2003 UK 87 38 (57.6) Median: 65
months — 9 deaths
occurred
5 deaths due
to CVD
Alamanos
et al. [16] 2003 North-west
Greece 221 108 (48.9) 1982–2001 — 4 deaths
occurred
2 deaths due
to CVD
Ali et al.
[15] 2007 Canada 680 385 (56.6) 1978–2004
Overall: 1.36 (1.12–1.64)
Male: 1.25 (0.95, 1.65)
Female: 1.47 (1.13, 1.91)
—
Malignancy
(23.6%),
CVD
(24.5%),
respiratory
diseases
(10.4%)
Wilson et
al. [9] 2009 US 147 90 (61) 1970–1999 0.91 (0.58, 1.37) — —
Buckley et
al. [14] 2010 UK 453 232 (51.2) 1985–2007
Overall: 0.82 (0.58–1.13)
Male: 0.68 (0.39, 1.10)
Female: 0.97 (0.60, 1.48)
—
CVD (38%),
respiratory
disease
(27%),
malignancy
(14%)
Ahlehoﬀ et
al. [17] 2010 Denmark 607 — 1997–2006 —
RR for
all-cause
mortality∗:
1.74
(1.32–2.30);
RR for car-
diovascular
death: 1.84
(1.11–3.06)
—
Mok et al.
[12] 2011 Hong Kong 778 424 (54) 1999–2008
Overall: 2.50 (1.81–3.19)
Male: 2.27 (1.44, 3.10)
Female: 2.76 (1.61, 3.91)
—
Infection
(33%),
malignancy
(20%), CVD
(20%)
SMR: standardized mortality ratio; CI: conﬁdence interval; UK: United Kingdom; CVD: cardiovascular disease; US: United States; RR: relative risk.
∗Rate ratio (95% conﬁdence interval) compared with 4,003,265 controls, adjusted for age, calendar year, concomitant medication, comorbidity, socio-
economic data and gender.
3.MortalityandCardiovascular
Mortality in PsA
Results from the current mortality studies in PsA yield
conﬂicting ﬁndings [3, 8–17]( Table 1). The study by Shbeeb
et al. on a small community-based incident cohort (n = 66)
of Minnestona, USA, found that the survival of patients
with PsA was not signiﬁcantly diﬀerent from that of the
general population [10]. A later study with a large sample
(n = 147) over 3 decades by the same group conﬁrmed this
ﬁnding [9]. The study by Buckley et al. on a cohort of 453
patients derived mainly from primary care also concludedInternational Journal of Rheumatology 3
that mortality of PsA did not diﬀer signiﬁcantly from that
of the general United Kingdom population [14]. However,
excess mortality in patients with PsA was documented in
several large studies [8, 12, 15, 17]. In a mortality study
of 428 patients with PsA from the University of Toronto
Psoriatic Arthritis Clinic with a mean follow-up of 11.4
years, the standardized mortality ratio (SMR) for the female
cohort was 1.59, and for the men, it was 1.65, indicating
a 59% and 65% increase, respectively, in the death rate
compared with the general population [8]. A later analysis
from the same cohort by Ali et al. showed improvement in
mortality over three decades, particularly for male patients
[15]. However, overall mortality still increased signiﬁcantly
in female patients and in the overall study cohort [15].
These conﬂicting ﬁndings may be partially explained by
the characteristics of the cohorts. The studies reporting no
increase in mortality in PsA are either having a small cohort
[9, 10] or more likely to represent early and less severe
stage of the disease in their cohorts [9, 14]. Since mortality
among patients with PsA is related to disease severity [18,
19], excess mortality is more likely to occur in clinic-based
cohorts with overrepresented severe PsA [15]. On the other
hand, the 2 studies in Denmark [17] and Hong Kong [12],
respectively, both using large nationwide registry database
and probably representing a broad spectrum of the disease,
conﬁrmedincreasedmortalityofPsAthanthatofthegeneral
population. The study in Denmark provided rate ratio for
mortality compared with over four million controls derived
from general population, adjusted for age, calendar year,
concomitant medication, comorbidity, socioeconomic data,
and gender [17]. Mortality in patients with PsA was found
similar to that in patients with psoriasis only [17]. Adjusted
SMRswereavailableinthestudybyAlietal.,wheremortality
rates were adjusted for radiological damage, erythrocyte sed-
imentationrate(ESR),presenceofhypertension,thenumber
ofactivelyinﬂamedjointandsmokingstatusatentryintothe
clinic [15]. Results were presented as the 10-year “rolling-
average” SMRs. After adjustment, the decline in mortality
over three decades remained evident in male patients, but
the decline was less marked for the overall population and
no decline was apparent for female patients [15].
The overall picture of the current mortality studies
suggests an increased in mortality among patients with
PsA. The excess mortality is predominantly due to CVD.
Majority of the previous studies found CVD as the leading
cause of death, responsible for 20% [12] to 56% [3]o f
all causes of death (Table 1). Cardiovascular mortality risk
ratio versus the general population was available in the study
by Wong et al. [8]. Cardiovascular mortality in PsA was
found 30% higher than that in the general population [8].
Deaths due to CVD were divided into myocardial infarction
(28%), cerebrovascular accidents (4%), and congestive heart
failure/atherosclerosis (4%) [8].
4.CardiovascularMorbidityinPsA
Data are limited regarding cardiovascular morbidity in
patients with PsA [20–24]. Han et al. investigated the
prevalence of CVD in 3,066 patients with PsA compared
to 12,264 healthy controls in a cross-sectional cohort [22].
The age- and sex-adjusted prevalence of chronic heart failure
(1.9 versus 1.3), ischemic heart disease (7.3 versus 5.5),
peripheral vascular disease (2.9 versus 1.9), cerebrovascular
disease (3.1 versus 2.3), type II diabetes (11.3 versus 7.3),
hyperlipidemia (27.8 versus 23.7), and hypertension (28.5
versus 22.3) was signiﬁcantly higher in patients with PsA
than that in healthy controls, indicating an increased risk
of cardiovascular morbidity. Gladman et al. conducted a
prospective study on prevalence of cardiovascular morbidity
on 648 patients of PsA with a mean follow-up of 8.3 years at
the University of Toronto Psoriatic Arthritic Clinic [23]. Two
hundred and twenty-seven patients had at least one cardio-
vascular condition (hypertension, cerebrovascular accident,
myocardial infarction, angina, or congestive heart failure),
corresponding to a prevalence of 35%. Increased prevalence
was observed for hypertension, myocardial infarction, and
angina with overall age and sex-adjusted standardized preva-
lence ratios of 1.9, 2.6, and 2.0, respectively. The prevalence
of cerebrovascular accident and congestive heart failure was
notfoundsigniﬁcantlyincreased.Twocross-sectionalstudies
found mixed association between PsA and cardiovascular
morbidity [20, 21]. Patients with PsA were not found to have
increased prevalence of CVD [20, 21] or diabetes mellitus
[20] but had increased prevalence of hypertension [20, 21]
and heart failure [20]. However, results from these two
studies should be interpreted with caution in view of the
relatively small samples (99 [20] and 165 [21] patients, resp.)
and the reliance on patient-reported information [21].
In summary, there is an increased prevalence of car-
diovascular morbidity and their risk factors in patients
with PsA when compared with general population. The
prevalence of CVD (including myocardial infarction, stroke,
and/or transient ischemic attack) in PsA (10%) was found
to resemble that in RA (12%) in a cross-sectional study
on 489 patients with PsA and 353 patients with RA [25].
The age- and sex-adjusted odds risk of CVD showed
no signiﬁcant diﬀerence between patients with RA and
those with PsA [25]. In a recent cross-sectional study by
Husted et al., prevalence of cardiovascular morbidities was
compared between 611 patients with PsA and 449 patients
with psoriasis only [24]. Results indicated signiﬁcantly
increased prevalence of hypertension (37.1% versus 19.6%),
obesity (30% versus 26.5%), hyperlipidemia (20.7% versus
14.5%), type 2 diabetes mellitus (12% versus 6.7%), and at
least 1 cardiovascular event (8.2% versus 3.3%, including
angina, myocardial infarction, cardiomyopathy, congestive
heart failure, and cerebrovascular accident) among patients
with PsA compared with those with psoriasis only. The
increased prevalence of hypertension remained signiﬁcant
after adjusted for demographics, psoriasis severity, and use
of medication. Overall, these ﬁndings tentatively support the
role of inﬂammatory arthritis in cardiovascular morbidity in
patients with PsA.
5.SubclinicalCVDinPsA
There are several literatures identifying subclinical CVD
which precedes overt cardiovascular events and mortality4 International Journal of Rheumatology
in patients with PsA. Results support that subclinical
atherosclerosis is accelerated in PsA.
Endothelial dysfunction is considered an early feature in
atherogenesis and has been consistently associated with car-
diovascular risk [26]. It encompasses an imbalance between
vasodilating and vasoconstricting substances, leading to an
impaired ability of the artery to dilate in response to physical
and chemical stimuli [26]. Postocclusion ﬂow-mediated
vasodilatation (FMD%) of the brachial artery using ultra-
sonography is used to noninvasively evaluate endothelial
function [27]. In the study by Gonzalez-Juanatey et al. in
50 patients with PsA without cardiovascular risk factors
or clinically evident CVD, FMD% was found signiﬁcantly
lower in patients with PsA compared with 50 matched
healthy controls, indicating endothelial dysfunction in PsA
as a potential basis for the association between PsA and
atherosclerosis [28].
Intima-media thickness (IMT) of the common carotid
artery, determined by ultrasonography, is a valuable non-
invasive surrogate marker of macrovascular atherosclerosis
disease [29]. IMT corresponds to the width of the vessel
intima and media, which is the site of lipid deposition and
plaque formation [30]. Increased carotid IMT is a good
indicator of generalized atherosclerosis and coronary artery
disease, providing early information on atherosclerosis in
subclinical stages of the disease [30] .A l lp r e v i o u sc a s e -
control studies, except 1 study involving a small sample
[31], have demonstrated that patients with PsA have a
higher prevalence of subclinical arthrosclerosis (Table 2).
The largest increase (23%) in carotid IMT in PsA was
found in a study by Tam et al. in a Chinese cohort [32].
The smallest increase in carotid IMT (8.7%) was found in
the study by Gonzalez-Juanatey et al. in patients with PsA
withoutcardiovascularriskfactorsorclinicallyevidentCVD,
signiﬁcantly higher than that in matched healthy controls
[33]. The prevalence of plaques in patients with PsA was also
signiﬁcantly increased compared with the healthy controls
[32]. There was a signiﬁcant linear trend of more severe
plaques among patients with PsA [34]. The increase in the
prevalence of plaque was not signiﬁcant in patients with PsA
withoutcardiovascularriskfactorsorclinicallyevidentCVD;
however, patients with PsA might be susceptible to more
unstable atherosclerotic plaques [33].
Arterial stiﬀness is independent predictors of the risk
of future fatal and nonfatal cardiovascular events and
total mortality in various patients group and may also
directly accelerate the atherosclerotic process [35]. The
pulse wave velocity (PWV) is determined by the elasticity
and other properties of the artery which correlate with
arterial distensibility and stiﬀness. An increase in aortic
PWV by 1 SD corresponds to an age-, sex-, and risk factor-
adjusted risk increase of 47%, 47%, and 42% in total
cardiovascularevents,cardiovascularmortality,andall-cause
mortality, respectively [36]. There is 1 recent case-control
study evaluating arterial stiﬀness, measured by aortic PWV,
in 20 patients with PsA in comparison to 20 matched healthy
controls [37]. A signiﬁcantly higher aortic PWV was found
in patients with PsA compared with controls (mean ± SD,
8.2 ± 0.8v e r s u s6 .8 ± 1.0m/s, P<0.001). The diﬀerence
remained signiﬁcant after adjusted for age, body weight,
body height, heart rate, and mean aortic pressure.
Results from conventional echocardiography in PsA are
controversial. The study by Gonzalez-Juanatey et al. did
not found signiﬁcant subclinical cardiac abnormalities in
50 patients with PsA without clinically evident CVD or
atherosclerosis risk factors when compared with 50 matched
healthy controls [38]. A recent study by Atzeni et al. reported
normal left ventricular wall thickness, size, mass, and systolic
function using standard 2D echocardiography in 22 patients
with PsA when compared with 35 healthy controls [31].
However, The study by Feld et al. found signiﬁcantly longer
PR interval (159.6 ± 21ms versus 151.3 ± 26ms) on electro-
cardiogram in 92 patients with PsA compared to 92 matched
controls [39]. The abnormal prolongation of the PR interval
was asymptomatic, requiring no additional intervention.
And there was no statistical diﬀerence in the ORS interval or
other atrial or ventricular conduction disturbance between
patients with PsA and controls [39]. The study by Shang
et al., by using both conventional echocardiography and
tissue Doppler imaging, found that 65% of 94 PsA patients
without established CVD had evidence of subclinical left
ventricular dysfunction, signiﬁcantly higher than that in
63 healthy controls [40]. Diastolic dysfunction appeared
(38%)morecommonthansystolicdysfunction(4%)andleft
ventricular dysfunction was more common in patients with
cardiovascular risk factors than in those without [40]. Mitral
valve prolapse was found in 14 out of 25 (56%) patients with
PsA,whereasonly2outof32(6%)psoriaticpatientswithout
arthritishadmitralvalveprolapse[41].Incontrast,thestudy
by Moya et al. found the prevalence of mitral valve prolapse
in 44 patients with PsA (4.5%) similar to that in the general
population [42].
6.Conventional CardiovascularRisk
Factors in PsA
It is apparent that patients with PsA have an increased
prevalence of conventional cardiovascular risk factors [5, 6,
22, 23, 43, 44]. These risk factors contribute to not only overt
but also subclinical CVD.
6.1. Hypertension and Diabetes Mellitus. The prevalence of
hypertension has been reported higher in patients with PsA
compared with that in the general population [20–23, 34,
43] or with that in patients with psoriasis only [24]. The
prevalence of diabetes mellitus was also found increased in
PsA in the majority of [22, 34, 43, 45], but not in all [20, 21]
of the previous studies. Tam et al. compared cardiovascular
risk factors in 102 patients with PsA and 82 healthy controls
[43].Afteradjustedforbodymassindex(BMI),patientswith
PsA were still more likely to have hypertension and diabetes
mellitus. Insulin resistance, measured by the Homeostasis
Model Assessment Index, was also signiﬁcantly increased
in patients with PsA compared with that in controls [43].
The presence of hypertension and diabetes mellitus has been
found signiﬁcantly associated with abnormal IMT (deﬁned
as IMT > 1.00mm in the study) in univariate analysis, butInternational Journal of Rheumatology 5
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the association became insigniﬁcant after adjusted for age
and waist circumference [46]. The presence of hypertension
was also found independently associated with subclinical left
ventricular dysfunction in patients with PsA [40].
6.2. Smoking, BMI, and Obesity. The prevalence of current
smoker was found not increased in several case-control
studies [31, 34, 47] and in a population study [20]b u t
was found signiﬁcantly increased (10% versus 0%) in a
case-control study by Tam et al. of 82 patients with PsA
and 82 healthy controls [32]. The study by Husted et al.
found a signiﬁcantly lower prevalence (12% versus 24.4%)
of current smoker in patients with PsA (n = 611) than in
those with psoriasis only (n = 449) [24]. The relationship
between smoking and (cardiovascular) mortality in PsA has
not been examined [18]. Gladman et al. found that current
smoking status was associated with an signiﬁcantly increased
risk of myocardial infarction with a hazard ratio of 15.89
[23]. But current smoking status did not increase the risk of
hypertension or CVD in PsA [23]. Overall, currently, the role
of smoking status in the increased cardiovascular risk in PsA
is understudied.
Increased BMI was found in 2 case-control studies by
Kimhi et al. [34] and Tam et al. [43]. Patients with PsA
were found to have a signiﬁcantly higher waist hip ratio
and a signiﬁcantly higher prevalence of overweight, obesity,
and abdominal obesity (according to the World Health
Organization criteria) [43] .Ah i g hB M Ia n do b e s i t yh a v e
been frequently found associated with an increased risk of
cardiovascular mortality and morbidity.
6.3. Metabolic Syndrome. The metabolic syndrome is a
cluster of traditional risk factors that include abdominal
obesity, atherogenic dyslipidemia, hypertension, and insulin
resistance. There are two studies investigating the prevalence
of metabolic syndrome in patients with PsA [44, 48].
The metabolic syndrome was deﬁned in both studies by
the recent joint consensus criteria [49], when ≥3 of the
following components were present: (1) elevated waist
circumferenceaccordingtopopulation-andcountry-speciﬁc
deﬁnitions; (2) elevated triglycerides level to ≥150mg/dL,
or therapy for elevated triglycerides; (3) reduced high-
density lipoprotein (HDL) cholesterol to <40mg/dL in men
and <50mg/dL in women; (4) elevated blood pressure,
systolic pressure ≥130mmHg, and/or diastolic pressure
≥85mmHg, or requiring drug therapy; and (5) elevated
fasting glucose to ≥100mg/dL. Raychaudhuri et al. reported
an increased prevalence (58.1%) of the metabolic syndrome
in 105 patients with PsA compared to the 35.2% reported
from the general population [48]. Mok et al. recently
reported that the prevalence of the metabolic syndrome was
signiﬁcantly higher in PsA (38% of 109 patients) compared
with matched controls (18% of 218 controls) or patients
with rheumatoid arthritis (RA) (20% of 699 patients) or
ankylosing spondylitis (AS) (11% of 122 patients) [44].
Patients with PsA were 2.44 times more likely to have the
metabolic syndrome relative to patients with RA or AS. They
had a higher risk of having central obesity, impaired fasting
glucose, hypertriglyceridemia, and reduced HDL cholesterol
level compared with patients with RA or AS [44].
6.4. Lipid. The data on lipid proﬁles in PsA are slightly
controversial. The prevalence of hyperlipidemia was found
higher in patients with PsA compared with that in general
population [22] or healthy controls [34]. The prevalence of
hypertriglyceridemia or hypercholesterolemia was found not
increased in PsA [43]. Increased levels of total cholesterol
[33] and triglyceride [32, 47] were found associated with
subclinical atherosclerosis in patients with PsA.
Jones et al. characterized the lipid proﬁle in 50 patients
with PsA and 50 age- and sex-matched controls and found
that HDL cholesterol and its third subfraction, HDL3
cholesterol, were signiﬁcantly reduced and the most dense
subfraction of low-density lipoprotein (LDL), LDL3,w a s
signiﬁcantly increased in the patients with PsA [50]. Sub-
analysis in 20 patients with active synovitis revealed signif-
icantly lower total cholesterol, LDL cholesterol, and HDL3
cholesterol in patients with PsA. Signiﬁcantly lower levels of
HDL cholesterol and its subfraction (both HDL3 cholesterol
and HDL2 cholesterol) were also found by Skoczy˜ nska et al.
in23patientswithPsAand23matchedhealthycontrols[51].
The case-control study by Tam et al., however, found that
patients with PsA had higher HDL cholesterol levels, lower
total cholesterol and LDL cholesterol levels, and a lower total
cholesterol/HDL cholesterol ratio [43].
A few studies have investigated the level of Lp(a) lipopro-
tein, apolipoprotein A I and apolipoprotein B. Jones et al.
found no signiﬁcant diﬀerences in the levels of apolipoprote-
in A I or B, the ratio of apolipoprotein A I:HDL cholesterol
or the ratio of apolipoprotein B:LDL cholesterol between
patients with PsA and matched controls [50]. Twenty-ﬁve
percent of the patients with PsA had raised Lp(a) lipoprotein
levels (>300mg/L) compared with 19% of controls, but
the diﬀerence was not statistically signiﬁcant. In contrast,
Tam et al. found signiﬁcantly increases in serum levels of
apolipoprotein A I and apolipoprotein B and the ratio of
apolipoprotein B: apolipoprotein A I in patients with PsA
[43]. Oliviero et al. investigated apolipoprotein A I and total
cholesterol in serum and synovial ﬂuid in 14 patients with
PsA and found that there was no statistically signiﬁcant
diﬀerence between patients and controls [52].
7. Nonconventional CardiovascularRisk
Factors in PsA
The increased cardiovascular risk in patients with PsA may
berelatedtotheinﬂammatoryprocess.Inﬂammationpartic-
ipates centrally in all stages of the development of atheroscle-
rosis, from the initial lesion to the end-stage thrombotic
complications [53]. The increased levels of proinﬂammatory
cytokines which are characteristics of chronic inﬂammatory
diseases such as PsA can elicit a systemic inﬂammatory state
that could, over time, promote atherosclerosis conducive to
increased cardiovascular risk. C-reactive protein (CRP) is
emerging as one of the predictors of CVD [54] and its levels
also relate well with joint inﬂammation [55]. Patients withInternational Journal of Rheumatology 7
PsA have signiﬁcantly higher level of CRP, as well as ESR,
another common maker of inﬂammation [28, 34, 47]. In a
mortality study in 428 patients with PsA by Gladman et al,
high ESR (>15mm/1st hour) was independently associated
with increased overall mortality [18]. Levels of CRP and ESR
were also found associated with subclinical atherosclerosis
(measured by carotid IMT) [34] or endothelial dysfunction
(measured by FMD%) [28] in patients with PsA. Tam
et al. reported that low-grade inﬂammation as measured
by high sensitivity CRP (hsCRP) was associated with an
increase in traditional cardiovascular risk factors including a
higher BMI, waist circumference,waist hip ratio, systolic and
diastolicbloodpressure,highersugarlevel,insulinresistance,
and dyslipidaemia (lower HDL cholesterol and apolipopro-
tein A I levels, higher total cholesterol/HDL ratio, and the
ratio of apolipoprotein B: apolipoprotein A I) [43]. Higher
hsCRPlevelwasalsoassociatedwithanincreasedthrombotic
tendency reﬂected by increased platelet count [43].
The increased prevalence of obesity in patients with PsA
may also increase the burden of inﬂammation [7]. Adipose
tissue cells secret cytokines, chemokines, and hormone-like
proteins which are involved in the adipose tissue homeo-
statis,in theregulationof insulin sensitivity and metabolism,
and also in the chronic inﬂammation [56]. It has been
found that high levels of proinﬂammatory cytokines, such
as tumor necrosis factor alpha (TNFα) and interleukin-6,
could down-regulate the production of adiponectin and,
on the other hand, upregulate the production of leptin,
which has a proinﬂammatory and pro-angiogenic role and
can accelerate endothelial dysfunction in patients with
inﬂammatory diseases [57].
Nitric oxide (NO) is the elusive mediator that causes
vascular dilatation. Endothelial dysfunction occurs when the
biological functions of NO are impaired [58]. Asymmetric
dimethylarginine (ADMA) is a competitive inhibitor of NO
synthesis [59]. Elevated levels of ADMA have been identiﬁed
as a risk marker for cardiovascular disease and mortality in
populations with high, intermediate, and low cardiovascular
risk [60–62]. Plasma ADMA level was found signiﬁcantly
higher in a small sample of 22 patients with PsA compared
with that in 35 healthy controls [31]. The level of ADMA was
negativelyassociatedwithcoronaryﬂowreserve,adiagnostic
marker for coronary artery disease, but not associated with
carotid IMT or disease activity or severity [31].
Fibrinogen is another acute-phase protein associated
with cardiovascular events [63]. The level of ﬁbrinogen
was found increased in patients with psoriasis and PsA [6]
and correlated with subclinical atherosclerosis (measured
by carotid IMT) [34]. Hyperhomocysteinemia confers an
independent cardiovascular risk similar to that of smoking
or hyperlipidemia [64] .I nas t u d yo fas m a l ln u m b e ro f
patients with inﬂammatory arthritis, including PsA and RA,
10 out of 15 (67%) patients had high level of homocysteine
(>15μmol/L) [65]. Asymptomatic hyperuricemia and serum
uric acid level were also found correlated with subclinical
atherosclerosisinpatientswithPsAwithoutclinicallyevident
CVD [66].
In conclusion, PsA is an inﬂammatory arthritis associ-
ated with increased risk for both overt and subclinical CVD.
Conventional risk factors probably occur more frequently
in patients with PsA; however, they only account partially
for the excess cardiovascular risk. Inﬂammation appears as
an important feature explaining the increased cardiovascular
risk in PsA, by directly participating in the development of
atherosclerosis and/or accentuating the established conven-
tional cardiovascular risk factors.
8.SubtypesofPsA andCardiovascularRisk
The 3 studies performed by the same group of Gonzalez-
Juanatey et al. subanalyzed the inﬂuence of the pattern of
arthritis of PsA on subclinical CVD, including subclinical
atherosclerosis (measured by carotid IMT) [33], endothelial
dysfunction (measured by FMD%) [28], and echocardio-
graphic and Doppler abnormalities [38]. Comparisons were
made between patients with polyarticular pattern and the
remaining patients with PsA. There was a lack of signiﬁcant
diﬀerences in carotid IMT and FMD% between the two
groups. There was also a lack of signiﬁcant diﬀerence in
echocardiographicandDopplerﬁndings,exceptthatpatients
with polyarticular pattern had smaller mean aortic root
diameter (28.8 ± 4.3mmversus32.5 ± 5.4mm, P value =
0.02) than in the rest of patients, probably due to the
predominance of women in the group of polyarticular
arthritis (58% versus 24%). The relationship between the
pattern of arthritis and abnormal carotid IMT (deﬁned as
IMT > 1.00mm) was studied by Mazlan et al. on 63 patients
with PsA [46]. The percentage of abnormal IMT did not
diﬀer signiﬁcantly between patients with polyarticular and
those with nonpolyarticular disease, between patients with
oligoarticular and those with nonoligoarticular disease, and
betweenpatientswithandthosewithoutspondylitis.Overall,
the pattern of arthritis appears to have limited inﬂuence on
cardiovascular risk in PsA.
9. Effect of Treatments on Cardiovascular
RiskinPsA
9.1. Nonsteroidal Anti-Inﬂammatory Drugs (NSAIDs) and
Disease-Modifying Antirheumatic Drugs (DMARDs). There
is evidence suggesting that NSAIDs including selective cyclo-
oxygenase-2 (COX2) inhibitors and traditional NSAIDs are
associated with increased risk of CVD. In a meta-analysis
of 138 randomized trials, selective COX2 inhibitors were
associated with a moderate increase (43%) in the risk
of severe cardiovascular events, mostly attributable to an
increased risk of myocardial infarction (odds ratio 1.86, 95%
conﬁdence interval 1.33–2.59) [67]. High-dose ibuprofen
and diclofenac, but not high-dose naproxen, were also
associated with excess cardiovascular events. However, there
is no study that speciﬁcally assesses the cardiovascular risk
related to NSAIDs in patients with PsA. The net eﬀects of
NSAIDs and COX2 inhibitors in patients with inﬂammatory
arthritis are diﬃcult to determine, because on one hand they
increase the cardiovascular risk, but on the other hand they
decrease the risk due to their favorable eﬀect on controlling
the disease. In a mortality study of PsA, the number of8 International Journal of Rheumatology
medications prior to the study was positively associated with
overall mortality rate [18]. However, increased mortality
associated with medications in PsA could not be fully
established since the number of medications could also be
a surrogate indicator of the severity of the disease, which is
associated with mortality [18]. Use of DMARDs, including
methotrexate, sulphasalazine, and leﬂunomide, was not
found associated with abnormal carotid IMT (deﬁned as
IMT > 1.00mm in the study) [46].
9.2.BiologicDMARDs. Previousﬁndingssupportthepivotal
role of inﬂammation in atherogenesis. However, till now,
evidence is not uniform and adequate studies are lacking to
supportthataggressiveanti-inﬂammationtherapy,including
biologic DMARDs, lowers the cardiovascular risk in patients
with PsA.
Results of the eﬀect of inﬂiximab on lipid proﬁle are
controversial. A reduction in HDL cholesterol and an eleva-
tion in total triglyceride, with no changes in total cholesterol
and LDL cholesterol, were reported in a 6-week prospective
study of 8 patients with PsA treated with inﬂiximab [68]. A
recent 24-week study of 15 patients with PsA treated with
inﬂiximabalsofoundsigniﬁcantlyincreasedtotaltriglyceride
levels, along with increased very-low-density lipoprotein
cholesterol level, but with no changes in total cholesterol,
LDLcholesterol,andHDLcholesterollevels[69].Incontrast,
a sustain increase in HDL with no signiﬁcant changes in
other lipids was reported in a 24-week study of 24 patients
withPsAtreatedwithinﬂiximab[70].Signiﬁcantweightgain
was observed in treatment of inﬂiximab and etanercept [71].
A12-weekrandomizeddouble-blind,placebo-controlled
clinical trial was conducted to examine the eﬀect of a
TNFα blocker, onercept, on cardiovascular risk factors in
127 patients with PsA [72]. Onercept at a dose of 100mg
induced signiﬁcant reductions in the levels of CRP, Lp(a)
lipoprotein, and homocysteine and an increase in the levels
of sex hormone binding globulin (as a surrogate marker of
insulin resistance) and apolipoprotein A I. But the level of
circulating adiponectin, an anti-inﬂammatory and poten-
tially antiatherogenic molecule, did not change signiﬁcantly
over time [73]. These data support an important precursor
role for high-grade inﬂammation in modulating the putative
risk parameters. However, the results also indicated that
treatment of onercept increased levels of triglyceride and
apolipoprotein B, which suggested that it was not possible
to prove the cardioprotective eﬀect of anti-TNFα therapies
on the basis of biochemical changes in isolation, and direct
measures of atherosclerotic progression such as carotid
ultrasonography would be preferred.
In a cross-sectional study, carotid IMT was higher in 104
patients with PsA on synthetic DMARDs than in those on
anti-TNFα therapy (120 patients) [74]. In a pilot prospective
study, Tam et al. showed that 12-week anti-TNFα therapy
may be associated with signiﬁcant reduction in carotid
IMT, along with improvement in clinical and laboratory
manifestations in patients with PsA [75]. The 2-year analysis
showed that further regression of the maximum IMT was
possible only in patients who were continued on long-term
anti-TNFα therapy, suggesting that eﬀective suppression of
inﬂammation in patients with high-grade inﬂammation may
potentially reverse early atherosclerotic lesions. Anti-TNFα
therapies were also shown to improve aortic stiﬀness [76, 77]
and modify the endothelial function [78] in small samples of
patients with inﬂammatory arthritis, including PsA.
10. Recommendations for Cardiovascular
Risk Management
The European League Against Rheumatism (EULAR) has
developed recommendations for cardiovascular risk man-
agement in patients with RA and other inﬂammatory
arthritis, including AS and PsA [79]. The EULAR rec-
ommendations recognize the association between inﬂam-
mation and atherosclerosis in patients with inﬂammatory
arthritis and recommend that aggressive suppression of
disease activity or inﬂammation is necessary to lower the
cardiovascular risk. Annual assessment of cardiovascular
risk using national guidelines is recommended for all
patients with PsA. Any risk factors identiﬁed should be
managed according to local guidelines. In the absence of
local guidelines, cardiovascular risk management should
follow the Systematic COronary Risk Evaluation (SCORE)
model. Unlike the Framingham risk score, in which the
pragmatic outcome bases on both cardiovascular mortality
and morbidity [80], the SCORE model estimates the 10-
year risk of developing cardiovascular death and includes the
following risk factors: age, gender, smoking habit, systolic
blood pressure, and either total cholesterol or the total
cholesterol/HDL cholesterol ratio [81]. Statins, angiotensin-
converting enzyme inhibitors, and/or angiotensin II blockers
are preferred treatment options due to their potential anti-
inﬂammatory eﬀects. Prescribing COX2 inhibitors and most
NSAIDs in patients with a documented CVD or in the
presence of cardiovascular risk factors should be cautious
due to their potential cardiovascular risk.
11. Conclusion
PsA is associated with an increased risk of clinical and
subclinical CVD mostly due to accelerated atherosclerosis.
Chronic inﬂammation plays a pivotal role in the
pathogenesis of atherosclerosis in PsA, acting independently
and/or synergistically with the traditional risk factors.
Large-scale prospective study is in need to identify risk
factors of CVD in PsA. There is a need for large long-term
interventional trials with cardiovascular end points to
investigate whether beneﬁts in articular disease achieved
by aggressive suppression of inﬂammation translate into
reduced cardiovascular risk in PsA.
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